Severe gastrointestinal bleeding due to erlotinib and celecoxib therapy: additional effect?
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related dead worldwide and accounts for over 85% of all lung cancers. Furthermore, the majority of patients with NSCLC present with advanced, metastatic disease at the time of diagnosis. For most patients with non-small cell lung canc...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2016-08-01
|
| Series: | Italian Journal of Medicine |
| Subjects: | |
| Online Access: | http://www.italjmed.org/index.php/ijm/article/view/689 |
| _version_ | 1827613454681243648 |
|---|---|
| author | Maddalena Zippi Angeloluca De Quarto Chiara Marzano Claudio Cassieri Pietro Crispino Giampiero Traversa Giuseppe Occhigrossi Paola Gnerre David Terracina |
| author_facet | Maddalena Zippi Angeloluca De Quarto Chiara Marzano Claudio Cassieri Pietro Crispino Giampiero Traversa Giuseppe Occhigrossi Paola Gnerre David Terracina |
| author_sort | Maddalena Zippi |
| collection | DOAJ |
| description | Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related dead worldwide and accounts for over 85% of all lung cancers. Furthermore, the majority of patients with NSCLC present with advanced, metastatic disease at the time of diagnosis. For most patients with non-small cell lung cancer, current treatments do not cure the cancer. Therefore, there is a great need for development of more effective therapies. The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) like erlotinib and gefitinib have been recognized as an important molecular target in cancer therapy and they are approved for the treatment of refractory advanced NSCLC patients. EGFR TKIs are generally well tolerated. The two most common toxicities include dermatologic and gastrointestinal side effects. Cases of gastrointestinal perforation, some of which were fatal, have also been reported in patients receiving erlotinib. Patients at increased risk include those taking concomitant anti-angiogenic agents, corticosteroids, non-steroidal anti-inflammatory drugs, and/or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease. |
| first_indexed | 2024-03-09T08:40:00Z |
| format | Article |
| id | doaj.art-7cde75f8b2464f7d8fcd693da04b2e72 |
| institution | Directory Open Access Journal |
| issn | 1877-9344 1877-9352 |
| language | English |
| last_indexed | 2024-03-09T08:40:00Z |
| publishDate | 2016-08-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Italian Journal of Medicine |
| spelling | doaj.art-7cde75f8b2464f7d8fcd693da04b2e722023-12-02T17:05:15ZengPAGEPress PublicationsItalian Journal of Medicine1877-93441877-93522016-08-01111757710.4081/itjm.2016.689567Severe gastrointestinal bleeding due to erlotinib and celecoxib therapy: additional effect?Maddalena Zippi0Angeloluca De Quarto1Chiara Marzano2Claudio Cassieri3Pietro Crispino4Giampiero Traversa5Giuseppe Occhigrossi6Paola Gnerre7David Terracina8Unit of Gastroenterology and Digestive Endoscopy, Sandro Pertini Hospital, RomaUnit of Oncology, Sandro Pertini Hospital, RomaUnit of Gastroenterology and Digestive Endoscopy, Sandro Pertini Hospital, RomaUnit of Gastroenterology and Digestive Endoscopy, Sandro Pertini Hospital, RomaUnit of Gastroenterology and Digestive Endoscopy, Sandro Pertini Hospital, RomaUnit of Gastroenterology and Digestive Endoscopy, Sandro Pertini Hospital, RomaUnit of Gastroenterology and Digestive Endoscopy, Sandro Pertini Hospital, RomaDepartment of Internal Medicine, San Paolo Hospital, SavonaUnit of Internal Medicine, Sandro Pertini Hospital, RomaNon-small cell lung cancer (NSCLC) is the leading cause of cancer-related dead worldwide and accounts for over 85% of all lung cancers. Furthermore, the majority of patients with NSCLC present with advanced, metastatic disease at the time of diagnosis. For most patients with non-small cell lung cancer, current treatments do not cure the cancer. Therefore, there is a great need for development of more effective therapies. The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) like erlotinib and gefitinib have been recognized as an important molecular target in cancer therapy and they are approved for the treatment of refractory advanced NSCLC patients. EGFR TKIs are generally well tolerated. The two most common toxicities include dermatologic and gastrointestinal side effects. Cases of gastrointestinal perforation, some of which were fatal, have also been reported in patients receiving erlotinib. Patients at increased risk include those taking concomitant anti-angiogenic agents, corticosteroids, non-steroidal anti-inflammatory drugs, and/or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease.http://www.italjmed.org/index.php/ijm/article/view/689Epidermal growth factor receptortyrosine kinase inhibitorserlotinibgastrointestinal bleedingnon-small cell lung cancercelecoxib. |
| spellingShingle | Maddalena Zippi Angeloluca De Quarto Chiara Marzano Claudio Cassieri Pietro Crispino Giampiero Traversa Giuseppe Occhigrossi Paola Gnerre David Terracina Severe gastrointestinal bleeding due to erlotinib and celecoxib therapy: additional effect? Italian Journal of Medicine Epidermal growth factor receptor tyrosine kinase inhibitors erlotinib gastrointestinal bleeding non-small cell lung cancer celecoxib. |
| title | Severe gastrointestinal bleeding due to erlotinib and celecoxib therapy: additional effect? |
| title_full | Severe gastrointestinal bleeding due to erlotinib and celecoxib therapy: additional effect? |
| title_fullStr | Severe gastrointestinal bleeding due to erlotinib and celecoxib therapy: additional effect? |
| title_full_unstemmed | Severe gastrointestinal bleeding due to erlotinib and celecoxib therapy: additional effect? |
| title_short | Severe gastrointestinal bleeding due to erlotinib and celecoxib therapy: additional effect? |
| title_sort | severe gastrointestinal bleeding due to erlotinib and celecoxib therapy additional effect |
| topic | Epidermal growth factor receptor tyrosine kinase inhibitors erlotinib gastrointestinal bleeding non-small cell lung cancer celecoxib. |
| url | http://www.italjmed.org/index.php/ijm/article/view/689 |
| work_keys_str_mv | AT maddalenazippi severegastrointestinalbleedingduetoerlotinibandcelecoxibtherapyadditionaleffect AT angelolucadequarto severegastrointestinalbleedingduetoerlotinibandcelecoxibtherapyadditionaleffect AT chiaramarzano severegastrointestinalbleedingduetoerlotinibandcelecoxibtherapyadditionaleffect AT claudiocassieri severegastrointestinalbleedingduetoerlotinibandcelecoxibtherapyadditionaleffect AT pietrocrispino severegastrointestinalbleedingduetoerlotinibandcelecoxibtherapyadditionaleffect AT giampierotraversa severegastrointestinalbleedingduetoerlotinibandcelecoxibtherapyadditionaleffect AT giuseppeocchigrossi severegastrointestinalbleedingduetoerlotinibandcelecoxibtherapyadditionaleffect AT paolagnerre severegastrointestinalbleedingduetoerlotinibandcelecoxibtherapyadditionaleffect AT davidterracina severegastrointestinalbleedingduetoerlotinibandcelecoxibtherapyadditionaleffect |